Abstract：
BACKGROUND: The present study aimed to investigate the in-vitro anti-diabetic, anti-cholinesterase, and anti-inflammatory potential of extracts from different parts of Ficus benghalensis, including leaves, stem, and roots, as well as isolated column fractions (F-B-1 C, F-B-2 C, F-B-3 C, and F-B-4 C).
METHODS: The extracts and subsequent fractions were evaluated for their inhibitory activity against key enzymes involved in diabetes [α-glucosidase and α-amylase], neurodegenerative diseases [acetylcholinesterase and butyrylcholinesterase], and inflammation (cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX)).
RESULTS: The results showed that F. benghalensis leaf extract exhibited the highest α-glucosidase inhibitory activity (73.84%) and α-amylase inhibitory activity (76.29%) at 1000 µg/mL. The stem extract (65.50%) and F-B-2 C fraction (69.67%) also demonstrated significant α-glucosidase inhibitory activity. In terms of anti-cholinesterase activity, the extracts of roots, leaves, and stem showed promising inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with half maximal inhibitory concentration (IC50) values ranging from 50.50 to 474.83 µg/mL. The derived fractions (F-B-1 C, F-B-2 C, F-B-3 C, and F-B-4 C) also exhibited notable inhibition of AChE and BChE, with IC50 values from 91.85 to 337.94 µg/mL. Moreover, the F-B-3 C fraction demonstrated the highest COX-2 inhibitory potential (85.72%), followed by F-B-1 C (83.13%), the stem extract (80.85%), and the leaves extract (79.00%). The F-B-1 C fraction showed the highest 5-LOX inhibitory activity (87.63%), while the root extract exhibited the lowest inhibition (73.39%).
CONCLUSIONS: The results demonstrated promising bioactivity, suggesting the potential of F. benghalensis as a source of natural compounds with therapeutic applications. Further studies are required to identify and isolate the active components responsible for these effects and to evaluate their in-vivo efficacy and safety.
METHODS: The extracts and subsequent fractions were evaluated for their inhibitory activity against key enzymes involved in diabetes [α-glucosidase and α-amylase], neurodegenerative diseases [acetylcholinesterase and butyrylcholinesterase], and inflammation (cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX)).
RESULTS: The results showed that F. benghalensis leaf extract exhibited the highest α-glucosidase inhibitory activity (73.84%) and α-amylase inhibitory activity (76.29%) at 1000 µg/mL. The stem extract (65.50%) and F-B-2 C fraction (69.67%) also demonstrated significant α-glucosidase inhibitory activity. In terms of anti-cholinesterase activity, the extracts of roots, leaves, and stem showed promising inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with half maximal inhibitory concentration (IC50) values ranging from 50.50 to 474.83 µg/mL. The derived fractions (F-B-1 C, F-B-2 C, F-B-3 C, and F-B-4 C) also exhibited notable inhibition of AChE and BChE, with IC50 values from 91.85 to 337.94 µg/mL. Moreover, the F-B-3 C fraction demonstrated the highest COX-2 inhibitory potential (85.72%), followed by F-B-1 C (83.13%), the stem extract (80.85%), and the leaves extract (79.00%). The F-B-1 C fraction showed the highest 5-LOX inhibitory activity (87.63%), while the root extract exhibited the lowest inhibition (73.39%).
CONCLUSIONS: The results demonstrated promising bioactivity, suggesting the potential of F. benghalensis as a source of natural compounds with therapeutic applications. Further studies are required to identify and isolate the active components responsible for these effects and to evaluate their in-vivo efficacy and safety.
摘要：
背景：本研究旨在研究体外抗糖尿病，抗胆碱酯酶,和抗炎的潜力，从不同部位的无花果提取物，包括树叶,茎,和根，以及分离的柱馏分(F-B-1C，F-B-2C,F-B-3C,和F-B-4C）。
方法：评估提取物和后续级分对糖尿病关键酶[α-葡萄糖苷酶和α-淀粉酶]的抑制活性，神经退行性疾病[乙酰胆碱酯酶和丁酰胆碱酯酶]，和炎症（环氧合酶-2（COX-2）和5-脂氧合酶（5-LOX））。
结果：结果表明，在1000µg/mL时，Benghalensis叶提取物表现出最高的α-葡萄糖苷酶抑制活性（73.84％）和α-淀粉酶抑制活性（76.29％）。茎提取物（65.50％）和F-B-2C部分（69.67％）也显示出显着的α-葡萄糖苷酶抑制活性。在抗胆碱酯酶活性方面，根的提取物，叶子,和茎显示有希望的抑制乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE），半最大抑制浓度（IC50）值范围为50.50至474.83µg/mL。导出的馏分(F-B-1C，F-B-2C,F-B-3C,和F-B-4C）对AChE和BChE也表现出明显的抑制作用，IC50值为91.85至337.94µg/mL。此外，F-B-3C部分表现出最高的COX-2抑制潜力（85.72％），其次是F-B-1C（83.13%），茎提取物（80.85%），和叶提取物(79.00%)。F-B-1C部分显示最高的5-LOX抑制活性（87.63%），而根提取物表现出最低的抑制作用（73.39％）。
结论：结果显示有希望的生物活性，这表明了F.benghalensis作为具有治疗应用的天然化合物来源的潜力。需要进一步的研究来鉴定和分离产生这些作用的活性成分，并评估其体内功效和安全性。
方法：评估提取物和后续级分对糖尿病关键酶[α-葡萄糖苷酶和α-淀粉酶]的抑制活性，神经退行性疾病[乙酰胆碱酯酶和丁酰胆碱酯酶]，和炎症（环氧合酶-2（COX-2）和5-脂氧合酶（5-LOX））。
结果：结果表明，在1000µg/mL时，Benghalensis叶提取物表现出最高的α-葡萄糖苷酶抑制活性（73.84％）和α-淀粉酶抑制活性（76.29％）。茎提取物（65.50％）和F-B-2C部分（69.67％）也显示出显着的α-葡萄糖苷酶抑制活性。在抗胆碱酯酶活性方面，根的提取物，叶子,和茎显示有希望的抑制乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE），半最大抑制浓度（IC50）值范围为50.50至474.83µg/mL。导出的馏分(F-B-1C，F-B-2C,F-B-3C,和F-B-4C）对AChE和BChE也表现出明显的抑制作用，IC50值为91.85至337.94µg/mL。此外，F-B-3C部分表现出最高的COX-2抑制潜力（85.72％），其次是F-B-1C（83.13%），茎提取物（80.85%），和叶提取物(79.00%)。F-B-1C部分显示最高的5-LOX抑制活性（87.63%），而根提取物表现出最低的抑制作用（73.39％）。
结论：结果显示有希望的生物活性，这表明了F.benghalensis作为具有治疗应用的天然化合物来源的潜力。需要进一步的研究来鉴定和分离产生这些作用的活性成分，并评估其体内功效和安全性。
